A Phase 1/2 interventional study of HS-10296 in Nonsmall Cell Lung Cancer, sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd.. Status unknown at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-23.
Sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd. (part of Hansoh Pharmaceutical Group Company Limited) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing aumolertinib in Carcinoma, Non-Small-Cell Lung — 13 open to participants now, 18 under way, 7 of them phase 3. aumolertinib · Carcinoma, Non-Small-Cell Lung.
Among the 29 studies testing aumolertinib in Carcinoma, Non-Small-Cell Lung, this one is the 7th largest by enrollment, is the only one that started in 2017, is the only one in phase 1/2, and was the 1st registered.
7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →13 of the 29 studies testing aumolertinib in Carcinoma, Non-Small-Cell Lung are open now, in 4 countries. Recruiting first, the newest first:
Sichuan University · Sites in China
Ages 18–75
Jiangsu Hansoh Pharmaceutical Co., Ltd. · Sites in Bosnia and Herzegovina, Bulgaria, Moldova
Ages 18+
Qianfoshan Hospital · Sites in China
Ages 18–75
West China Hospital · Sites in China
Ages 18+
Jiangsu Hansoh Pharmaceutical Co., Ltd. · Sites in China
Ages 18+
By country, each count listing its studies:
aumolertinib: first EMA approval 2026. What it is approved for, and how studies give it, is on its page →
Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 15 · Phase 3 11
First in 2017; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 364 is above the median of 62 across 6,028 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 150 across the 29 interventional studies. None of them has completed or been terminated yet.
This tab as a report to print or save as PDF → With an account.
11 of 29 have an industry lead sponsor. The 10 most frequent:
This study is registered under Jiangsu Hansoh Pharmaceutical Co., Ltd., one of the names counted as Hansoh Pharmaceutical Group Company Limited. Under that name alone:
Jiangsu Hansoh Pharmaceutical Co., Ltd. is the lead sponsor of 138 studies on the registry; 72 are open to participants now.
26 studies in Carcinoma, Non-Small-Cell Lung by Hansoh Pharmaceutical Group Company Limited: 20 open now, 22 under way, 8 of them phase 3.
Among the 26 studies in Carcinoma, Non-Small-Cell Lung by Hansoh Pharmaceutical Group Company Limited, this one is the 9th largest by enrollment, is the only one that started in 2017, is one of 3 in phase 1/2, and was the 1st registered.
Hansoh Pharmaceutical Group Company Limited’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2017.
2 of the studies testing aumolertinib in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06752408Peking Union Medical College HospitalAumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung Cancer | 2027-01-16 |
| NCT06951464Sichuan UniversityA Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC | 2027-05-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 29 studies testing aumolertinib in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Hansoh Pharmaceutical Group Company Limited’s 26 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
This is a Phase 1/2, open-label, multicenter study of HS-10296 with dose escalation, dose expansion and extension cohorts in locally advanced or metastatic non-small-cell lung cancer (NSCLC) patients who have progressed following prior therapy with an epidermal growth factor receptor(EGFR) tyrosine kinase inhibitor (TKI) agent. The study is designed to evaluate safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of once-daily and orally (PO) administered HS-10296. The overall study design is shown in the flow chart below, which consists of 3 phases: dose escalation, dose expansion and extension cohort.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients must fulfill one of the following:
For the dose expansion and extension cohorts, patients also must have confirmation of tumor T790M+ mutation status from a sample taken after disease progression on the most recent treatment regimen with an EGFR TKI.
Prior to entry, a result from the central analysis of the patient's T790M mutation status must be obtained.
Females of should be using adequate measures throughout the study, should not be breast feeding at the time of screening, during the study and until 3 months after completion of study, and must have a negative pregnancy test prior to start of dosing if of child-bearing potential or must have evidence of non-child-bearing potential by fulfilling 1 of the following criteria at screening:
For the dose expansion paired biopsy cohort:
Exclusion Criteria:
Treatment with any of the following:
Any of the following cardiac criteria:
Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values:
The following are considered criteria for exclusion from the exploratory genetic research:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral Once-Daily Administration of HS-10296 55mg
Drug: HS-10296
Oral Once-Daily Administration of HS-10296 110mg
Drug: HS-10296
Oral Once-Daily Administration of HS-10296 220mg
Drug: HS-10296
Oral Once-Daily Administration of HS-10296 260mg
Drug: HS-10296
Oral Once-Daily Administration of HS-10296 55mg
Drug: HS-10296
Oral Once-Daily Administration of HS-10296 110mg
Drug: HS-10296
Oral Once-Daily Administration of HS-10296 220mg
Drug: HS-10296
Oral Once-Daily Administration of HS-10296 110mg (RP2D)
Drug: HS-10296
HS-10296: 5-, 10-, 40-, and 55-mg tablet, immediate-release formulation. Patients should avoid consumption of food for at least 1 hour prior to and 2 hours post dosing. RP2D is determined at 110 mg QD.
Number of Participants With Dose Limiting Toxicity (DLT) Phase I Part
DLT is defined as one of the following HS-10296 related adverse event (AE) :(1) Hematological toxicity ≥ Grade 4 neutropenia lasting more than 5 days, febrile neutropenia of any duration (absolute neutrophil count \[ANC\]) \< 1.0 × 109/L and fever ≥ 38.5°C), Grade 4 thrombocytopenia, Grade 3 thrombocytopenia with bleeding, any requirement for platelet transfusion, Grade 4 anemia (unexplained by underlying disease); (2)Non-hematological toxicity ≥ CTCAE Grade 3 including Infection (including febrile neutropenia), confirmed prolongation of QT interval corrected with Fridericia's (QTcF) (\> 500 ms absolute or \> 60 ms above Baseline) and cardiac toxicity greater than Grade 3;(3)Any other toxicity that is greater than that at Baseline (clinically significant and/or unacceptable, and judged to be a DLT by the SRC), meets a protocol-defined stopping criteria (i.e., confirmed corneal ulceration), or results in a disruption of dosing schedule of more than 7 days.
Time frame: 21 days
Overall Response Rate (ORR) Phase II Part
ORR is defined as the percentage of patients with a complete response (CR) or partial response (PR) that was confirmed at a subsequent scan at least 6 weeks later, as assessed according to RECIST (Response Evaluation Criteria In Solid Tumors Criteria) version 1.1 for target lesions and assessed by CT/MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Time frame: From the date of first dose until the date of disease progression or withdrawal from study, approximately 15 months
Incidence and Severity of Adverse Events (AEs) Phase I Part
An AE is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product. An undesirable medical condition can be symptoms (e.g., nausea, chest pain), signs (e.g., tachycardia, enlarged liver), or the abnormal results of an investigation (e.g., laboratory findings, ECG). Any deterioration of the disease under study and associated symptoms or findings should not be regarded as an AE as far as the deterioration can be anticipated. The AE was graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0.
Time frame: From the screening period to 28 days after treatment completion, approximately 16 months
Area Under the Plasma Concentration Versus Time Curve (AUC) of HS-10296 and HAS-719 From Zero to the 24-Hour Sampling Time (AUC0-24) After Single Dose of HS-10296
Area under the plasma concentration versus time curve from time zero to the 24-hour sampling time at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-24 was to be calculated according to the mixed log-linear trapezoidal rule.
Time frame: From pre-dose to 24 hours after single dose on Day 1 of Cycle 0
Elimination Half-life(T1/2) of HS-10296 and HAS-719
Elimination half-life is the time measured for the concentration to decrease by one half. Half-life calculated by natural log 2 divided by λz.
Time frame: From pre-dose to 120 hours after single dose on Day 1 of Cycle 0
Css Max of HS-10296 and HAS-719 After Multiple Dose
Observed maximum plasma concentration (Css max) after multiple dose of HS-10296 and HAS-719
Time frame: From pre-dose to 21 days after multiple dose on Day 1 of Cycle 2
AUCss of HS-10296 and HAS-719 After Multiple Dose of HS-10296
Area Under the Plasma Concentration Versus Time Curve at steady state (AUCss) of HS-10296 and HAS-719 after multiple dose of HS-10296
Time frame: From pre-dose to 21 days after multiple dose on Day 1 of Cycle 2
Overall Response Rate (Phase I Part)
ORR is defined as the percentage of patients with a complete response (CR) or partial response (PR) that was confirmed at a subsequent scan at least 6 weeks later, as assessed according to RECIST (Response Evaluation Criteria In Solid Tumors Criteria) version 1.1 for target lesions and assessed by CT/MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Time frame: From the date of first dose until the date of disease progression or withdrawal from study, approximately 15 months
Progression-free Survival (PFS)
The PFS is defined as the time from date of first dosing until the date of objective disease progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or death (by any cause in the absence of progression) regardless of whether the patients withdraws from HS-10296 therapy or receives another anti-cancer therapy prior to progression. Progression is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Time frame: From the date of enrollment until the date of disease progression or death from any cause, approximately 15 months
Disease Control Rate (DCR)
Objective response is assessed by RECIST 1.1 thereby to evaluate disease control rate. The DCR is defined as the proportion of patients with a best overall response of CR, PR, or SD (stable disease).
Time frame: From the date of first dose until the date of disease progression or withdrawal from study, approximately 15 months
Overall Survival (OS) Phase II Part
Overall survival will be assessed based on the date of first dose and survival status at the time of analysis. Overall survival is defined as the time from date of first dose until the documentation of death from any cause.
Time frame: From the date of enrollment until the date of death from any cause, approximately 48 months
Depth of Response (DepOR)
Depth of Response (DepOR) Only in part II dose-extention phase. DepOR is defined as the percentage change in tumor size, based on longest diameter or reconstructed volume, observed at the lowest point compared with baseline.
Time frame: From the date of enrollment until the date of disease progression or death, approximately 15 months
Duration of Response (DoR)
Duration of response (DoR) is defined as the time from the date of first documented response until the date of documented progression or death in the absence of disease progression. The end of response should coincide with the date of progression or death from any cause used for the PFS endpoint. The time of the initial response will be defined as the latest of the dates contributing towards the first visit response of PR or CR. If a patient does not progress following a response, then DoR will be used as the PFS censoring time.
Time frame: From the date of enrollment until the date of disease progression or death, approximately 18 months
Incidence and Severity of AEs Phase II Part
An AE is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product. An undesirable medical condition can be symptoms (e.g., nausea, chest pain), signs (e.g., tachycardia, enlarged liver), or the abnormal results of an investigation (e.g., laboratory findings, ECG). Any deterioration of the disease under study and associated symptoms or findings should not be regarded as an AE as far as the deterioration can be anticipated. The AE was graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0.
Time frame: From the screening period to 28 days after treatment completion, approximately 16 months
A total of 364 patients were enrolled at 47 centers in 2 countries.
| Milestone | Escalation Cohort 1 | Escalation Cohort 2 | Escalation Cohort 3 | Escalation Cohort 4 | Expansion Cohort 1 | Expansion Cohort 2 | Expansion Cohort 3 | Phase 2 Extension |
|---|---|---|---|---|---|---|---|---|
| Started | 6 | 6 | 8 | 6 | 30 | 33 | 31 | 244 |
| Completed | 5 | 6 | 7 | 6 | 21 | 15 | 13 | 62 |
| Not completed | 1 | 0 | 1 | 0 | 9 | 18 | 18 | 182 |
DLT is defined as one of the following HS-10296 related adverse event (AE) :(1) Hematological toxicity ≥ Grade 4 neutropenia lasting more than 5 days, febrile neutropenia of any duration (absolute neutrophil count \[ANC\]) \< 1.0 × 109/L and fever ≥ 38.5°C), Grade 4 thrombocytopenia, Grade 3 thrombocytopenia with bleeding, any requirement for platelet transfusion, Grade 4 anemia (unexplained by underlying disease); (2)Non-hematological toxicity ≥ CTCAE Grade 3 including Infection (including febrile neutropenia), confirmed prolongation of QT interval corrected with Fridericia's (QTcF) (\> 500 ms absolute or \> 60 ms above Baseline) and cardiac toxicity greater than Grade 3;(3)Any other toxicity that is greater than that at Baseline (clinically significant and/or unacceptable, and judged to be a DLT by the SRC), meets a protocol-defined stopping criteria (i.e., confirmed corneal ulceration), or results in a disruption of dosing schedule of more than 7 days.
| Participants | Escalation Cohort 1 | Escalation Cohort 2 | Escalation Cohort 3 | Escalation Cohort 4 |
|---|---|---|---|---|
| Number of Participants With Dose Limiting Toxicity (DLT) Phase I Part | 0 | 0 | 1 | 1 |
ORR is defined as the percentage of patients with a complete response (CR) or partial response (PR) that was confirmed at a subsequent scan at least 6 weeks later, as assessed according to RECIST (Response Evaluation Criteria In Solid Tumors Criteria) version 1.1 for target lesions and assessed by CT/MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
| percentage of participants | Phase 2 Extension |
|---|---|
| Overall Response Rate (ORR) Phase II Part | 65.6 (59.2 to 71.5) |
An AE is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product. An undesirable medical condition can be symptoms (e.g., nausea, chest pain), signs (e.g., tachycardia, enlarged liver), or the abnormal results of an investigation (e.g., laboratory findings, ECG). Any deterioration of the disease under study and associated symptoms or findings should not be regarded as an AE as far as the deterioration can be anticipated. The AE was graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0.
| Participants | Escalation Cohort 1 | Escalation Cohort 2 | Escalation Cohort 3 | Escalation Cohort 4 | Expansion Cohort 1 | Expansion Cohort 2 | Expansion Cohort 3 |
|---|---|---|---|---|---|---|---|
| At least one adverse event | 6 | 6 | 8 | 6 | 30 | 32 | 31 |
| At least one adverse event of Grade 3 or greater | 1 | 1 | 3 | 3 | 6 | 8 | 11 |
| At least one serious adverse event | 2 | 1 | 2 | 3 | 5 | 6 | 3 |
Area under the plasma concentration versus time curve from time zero to the 24-hour sampling time at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-24 was to be calculated according to the mixed log-linear trapezoidal rule.
| h*ng/mL | Escalation Cohort 1 | Escalation Cohort 2 | Escalation Cohort 3 | Escalation Cohort 4 |
|---|---|---|---|---|
| HS-10296 | 1740.1175 ± 917.7303 | 5250.2364 ± 3345.8348 | 8174.4312 ± 8126.7012 | 8038.9348 ± 1648.4566 |
| HAS-719 | 298.4934 ± 131.6189 | 696.4536 ± 293.4756 | 1152.1150 ± 475.5067 | 1564.3829 ± 488.6330 |
Elimination half-life is the time measured for the concentration to decrease by one half. Half-life calculated by natural log 2 divided by λz.
| hours | Escalation Cohort 1 | Escalation Cohort 2 | Escalation Cohort 3 | Escalation Cohort 4 |
|---|---|---|---|---|
| HS-10296 | 31.29 ± 9.57 | 30.62 ± 9.34 | 35.19 ± 13.89 | 34.81 ± 9.76 |
| HAS-719 | 49.75 ± 10.70 | 55.36 ± 19.95 | 63.75 ± 29.83 | 57.79 ± 13.95 |
Observed maximum plasma concentration (Css max) after multiple dose of HS-10296 and HAS-719
| ng/mL | Escalation Cohort 1 | Escalation Cohort 2 | Escalation Cohort 3 | Escalation Cohort 4 | Expansion Cohort 1 | Expansion Cohort 2 | Expansion Cohort 3 | Phase 2 Extension |
|---|---|---|---|---|---|---|---|---|
| HS-10296 | 164.5000 ± 70.6222 | 352.8333 ± 102.7062 | 762.0000 ± 231.8888 | 765.4000 ± 285.2802 | 197.9308 ± 78.6513 | 413.2751 ± 194.0200 | 552.0635 ± 257.9572 | 352.5111 ± 185.3279 |
| HAS-719 | 55.3500 ± 18.1391 | 118.1333 ± 26.9018 | 276.1667 ± 42.9391 | 338.2000 ± 119.3302 | 62.9535 ± 21.4094 | 142.1545 ± 49.4867 | 221.9404 ± 83.6900 | 118.3758 ± 43.3468 |
Area Under the Plasma Concentration Versus Time Curve at steady state (AUCss) of HS-10296 and HAS-719 after multiple dose of HS-10296
| h*ng/mL | Escalation Cohort 1 | Escalation Cohort 2 | Escalation Cohort 3 | Escalation Cohort 4 | Expansion Cohort 1 | Expansion Cohort 2 | Expansion Cohort 3 | Phase 2 Extension |
|---|---|---|---|---|---|---|---|---|
| HS-10296 | 2488.0953 ± 439.3443 | 7000.2498 ± 2832.8180 | 11994.8801 ± 3839.4164 | 14101.8608 ± 5294.1409 | 3550.8674 ± 1451.0173 | 7098.0738 ± 2826.1228 | 10185.6761 ± 4862.0070 | 6602.2491 ± 3482.0499 |
| HAS-719 | 983.7103 ± 201.9267 | 2691.7220 ± 677.2407 | 5458.2304 ± 659.3078 | 8154.0849 ± 1144.0617 | 1304.4143 ± 429.1216 | 2852.8083 ± 820.1842 | 4692.6023 ± 1771.6881 | 2467.8527 ± 892.5071 |
ORR is defined as the percentage of patients with a complete response (CR) or partial response (PR) that was confirmed at a subsequent scan at least 6 weeks later, as assessed according to RECIST (Response Evaluation Criteria In Solid Tumors Criteria) version 1.1 for target lesions and assessed by CT/MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
| percentage of participants | Escalation Cohort 1 | Escalation Cohort 2 | Escalation Cohort 3 | Escalation Cohort 4 | Expansion Cohort 1 | Expansion Cohort 2 | Expansion Cohort 3 |
|---|---|---|---|---|---|---|---|
| Overall Response Rate (Phase I Part) | 50.0 (11.8 to 88.2) | 66.7 (22.3 to 95.7) | 37.5 (8.5 to 75.5) | 16.7 (0.4 to 64.1) | 60.0 (40.6 to 77.3) | 54.5 (36.4 to 71.9) | 41.9 (24.5 to 60.9) |
The PFS is defined as the time from date of first dosing until the date of objective disease progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or death (by any cause in the absence of progression) regardless of whether the patients withdraws from HS-10296 therapy or receives another anti-cancer therapy prior to progression. Progression is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
| months | Escalation Cohort 1 | Escalation Cohort 2 | Escalation Cohort 3 | Escalation Cohort 4 | Expansion Cohort 1 | Expansion Cohort 2 | Expansion Cohort 3 | Phase 2 Extension |
|---|---|---|---|---|---|---|---|---|
| Progression-free Survival (PFS) | 11.2 (3.0 to NA) | 7.0 (5.8 to 12.5) | 5.5 (1.1 to 8.4) | 3.7 (0.8 to 11.0) | 9.6 (6.7 to 15.1) | 13.6 (6.9 to 19.2) | 11.1 (8.3 to 24.8) | 12.4 (9.7 to 15.0) |
Objective response is assessed by RECIST 1.1 thereby to evaluate disease control rate. The DCR is defined as the proportion of patients with a best overall response of CR, PR, or SD (stable disease).
| percentage of participants | Escalation Cohort 1 | Escalation Cohort 2 | Escalation Cohort 3 | Escalation Cohort 4 | Expansion Cohort 1 | Expansion Cohort 2 | Expansion Cohort 3 | Phase 2 Extension |
|---|---|---|---|---|---|---|---|---|
| Disease Control Rate (DCR) | 100.0 (54.1 to 100.0) | 100.0 (54.1 to 100.0) | 75.0 (34.9 to 96.8) | 50.0 (11.8 to 88.2) | 83.3 (65.3 to 94.4) | 97.0 (84.2 to 99.9) | 93.5 (78.6 to 99.2) | 93.4 (89.6 to 96.2) |
Overall survival will be assessed based on the date of first dose and survival status at the time of analysis. Overall survival is defined as the time from date of first dose until the documentation of death from any cause.
| months | Phase 2 Extension |
|---|---|
| Overall Survival (OS) Phase II Part | 31.5 (25.9 to 35.7) |
Depth of Response (DepOR) Only in part II dose-extention phase. DepOR is defined as the percentage change in tumor size, based on longest diameter or reconstructed volume, observed at the lowest point compared with baseline.
| percentage of change from baseline | Phase 2 Extension |
|---|---|
| Depth of Response (DepOR) | -47.89 ± 22.333 |
Duration of response (DoR) is defined as the time from the date of first documented response until the date of documented progression or death in the absence of disease progression. The end of response should coincide with the date of progression or death from any cause used for the PFS endpoint. The time of the initial response will be defined as the latest of the dates contributing towards the first visit response of PR or CR. If a patient does not progress following a response, then DoR will be used as the PFS censoring time.
| months | Escalation Cohort 1 | Escalation Cohort 2 | Escalation Cohort 3 | Escalation Cohort 4 | Expansion Cohort 1 | Expansion Cohort 2 | Expansion Cohort 3 | Phase 2 Extension |
|---|---|---|---|---|---|---|---|---|
| Duration of Response (DoR) | 13.9 (1.9 to NA) | 5.6 (4.2 to 9.5) | 5.6 (4.1 to 7.0) | 5.5 (NA to NA) | 8.3 (8.1 to 16.5) | 12.5 (5.5 to 22.1) | 22.1 (8.1 to 35.7) | 15.1 (12.9 to 16.6) |
An AE is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product. An undesirable medical condition can be symptoms (e.g., nausea, chest pain), signs (e.g., tachycardia, enlarged liver), or the abnormal results of an investigation (e.g., laboratory findings, ECG). Any deterioration of the disease under study and associated symptoms or findings should not be regarded as an AE as far as the deterioration can be anticipated. The AE was graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0.
| Participants | Phase 2 Extension |
|---|---|
| At least 1 adverse event | 219 |
| At least one adverse event of Grade 3 or greater | 60 |
| At least one serious adverse event | 30 |
Collected over Throughout the study, from informed consent until the end of the follow-up period. The follow-up period is defined as 28 ± 3 days after study treatment is discontinued, assessed up to 16 months. Deaths were assessed up to 48 months. Serious and Other (Non-Serious) Adverse Events were assessed up to 16 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Escalation Cohort 1 | 0/6 (0%) | 2/6 (33.3%) | 6/6 (100%) |
| Escalation Cohort 2 | 0/6 (0%) | 1/6 (16.7%) | 6/6 (100%) |
| Escalation Cohort 3 | 0/8 (0%) | 2/8 (25%) | 8/8 (100%) |
| Escalation Cohort 4 | 0/6 (0%) | 3/6 (50%) | 6/6 (100%) |
| Expansion Cohort 1 | 0/30 (0%) | 5/30 (16.7%) | 29/30 (96.7%) |
| Expansion Cohort 2 | 0/33 (0%) | 6/33 (18.2%) | 31/33 (93.9%) |
| Expansion Cohort 3 | 0/31 (0%) | 3/31 (9.7%) | 29/31 (93.5%) |
| Phase 2 Extension | 11/244 (4.5%) | 30/244 (12.3%) | 193/244 (79.1%) |
| Event | Escalation Cohort 1 | Escalation Cohort 2 | Escalation Cohort 3 | Escalation Cohort 4 | Expansion Cohort 1 | Expansion Cohort 2 | Expansion Cohort 3 | Phase 2 Extension |
|---|---|---|---|---|---|---|---|---|
| PneumonitisInfections and infestations | 1/6 | 0/6 | 1/8 | 1/6 | 0/30 | 0/33 | 0/31 | 5/244 |
| SepsisInfections and infestations | 0/6 | 0/6 | 0/8 | 1/6 | 0/30 | 0/33 | 0/31 | 0/244 |
| Urinary tract infectionInfections and infestations | 1/6 | 0/6 | 0/8 | 0/6 | 0/30 | 1/33 | 0/31 | 0/244 |
| PresyncopeNervous system disorders | 0/6 | 0/6 | 0/8 | 1/6 | 0/30 | 0/33 | 0/31 | 1/244 |
| Bowel obstructionGastrointestinal disorders | 1/6 | 0/6 | 0/8 | 0/6 | 0/30 | 0/33 | 0/31 | 0/244 |
| Peripheral swellingGeneral disorders | 0/6 | 0/6 | 0/8 | 1/6 | 0/30 | 0/33 | 0/31 | 0/244 |
| Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders | 0/6 | 0/6 | 0/8 | 1/6 | 0/30 | 0/33 | 0/31 | 0/244 |
| Deep vein thrombosisVascular disorders | 0/6 | 1/6 | 0/8 | 0/6 | 0/30 | 0/33 | 0/31 | 2/244 |
| Deep vein thrombosisVascular disorders | 0/6 | 1/6 | 0/8 | 0/6 | 0/30 | 0/33 | 0/31 | 0/244 |
| IleusGastrointestinal disorders | 1/6 | 0/6 | 0/8 | 0/6 | 0/30 | 0/33 | 0/31 | 0/244 |
| Event | Escalation Cohort 1 | Escalation Cohort 2 | Escalation Cohort 3 | Escalation Cohort 4 | Expansion Cohort 1 | Expansion Cohort 2 | Expansion Cohort 3 | Phase 2 Extension |
|---|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 0/6 | 0/6 | 2/8 | 4/6 | 0/30 | 4/33 | 5/31 | 15/244 |
| ConstipationGastrointestinal disorders | 2/6 | 2/6 | 3/8 | 0/6 | 3/30 | 3/33 | 2/31 | 20/244 |
| TachycardiaCardiac disorders | 0/6 | 0/6 | 1/8 | 2/6 | 0/30 | 0/33 | 0/31 | 0/244 |
| Abdominal pain upperGastrointestinal disorders | 1/6 | 2/6 | 1/8 | 0/6 | 0/30 | 0/33 | 0/31 | 0/244 |
| DiarrhoeaGastrointestinal disorders | 2/6 | 1/6 | 2/8 | 0/6 | 3/30 | 5/33 | 7/31 | 11/244 |
| ParonychiaInfections and infestations | 2/6 | 0/6 | 1/8 | 0/6 | 1/30 | 0/33 | 4/31 | 0/244 |
| Upper respiratory tract infectionInfections and infestations | 2/6 | 2/6 | 0/8 | 0/6 | 6/30 | 2/33 | 3/31 | 32/244 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 2/6 | 0/6 | 0/8 | 1/6 | 3/30 | 3/33 | 8/31 | 0/244 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/6 | 2/6 | 1/8 | 0/6 | 6/30 | 4/33 | 7/31 | 25/244 |
| RashSkin and subcutaneous tissue disorders | 0/6 | 2/6 | 0/8 | 0/6 | 5/30 | 6/33 | 6/31 | 30/244 |
| Age, Categorical(Participants) | Escalation Cohort 1 | Escalation Cohort 2 | Escalation Cohort 3 | Escalation Cohort 4 | Expansion Cohort 1 | Expansion Cohort 2 | Expansion Cohort 3 | Phase 2 Extension | Total |
|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 3 | 4 | 5 | 4 | 22 | 16 | 21 | 153 | 228 |
| >=65 years | 3 | 2 | 3 | 2 | 8 | 17 | 10 | 91 | 136 |
| Sex: Female, Male(Participants) | Escalation Cohort 1 | Escalation Cohort 2 | Escalation Cohort 3 | Escalation Cohort 4 | Expansion Cohort 1 | Expansion Cohort 2 | Expansion Cohort 3 | Phase 2 Extension | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 5 | 3 | 5 | 5 | 19 | 20 | 20 | 142 | 219 |
| Male | 1 | 3 | 3 | 1 | 11 | 13 | 11 | 102 | 145 |
| Race (NIH/OMB)(Participants) | Escalation Cohort 1 | Escalation Cohort 2 | Escalation Cohort 3 | Escalation Cohort 4 | Expansion Cohort 1 | Expansion Cohort 2 | Expansion Cohort 3 | Phase 2 Extension | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 5 | 6 | 7 | 5 | 29 | 31 | 31 | 244 | 358 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Black or African American | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| White | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 4 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Escalation Cohort 1 | Escalation Cohort 2 | Escalation Cohort 3 | Escalation Cohort 4 | Expansion Cohort 1 | Expansion Cohort 2 | Expansion Cohort 3 | Phase 2 Extension | Total |
|---|---|---|---|---|---|---|---|---|---|
| United States | 1 | 0 | 2 | 1 | 1 | 2 | 0 | 0 | 7 |
| Taiwan | 5 | 6 | 5 | 5 | 13 | 17 | 18 | 55 | 124 |
| China | 0 | 0 | 1 | 0 | 16 | 14 | 13 | 189 | 233 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2017 to primary completion in Jan 2019, 19 months.
Results were first posted in Jan 2023, 4 years after primary completion.
Of 311 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's 19 months is below that.
Counting every sponsor, half of 434 studies reached it within 62 months; a quarter within 41 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aumolertinib
Carcinoma, Non-Small-Cell Lung →
Jiangsu Hansoh Pharmaceutical Co., Ltd. →